Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2009

Open Access 01-12-2009 | Research article

Determinants of cardiac troponin T elevation in COPD exacerbation – a cross-sectional study

Authors: Pål H Brekke, Torbjørn Omland, Stein Harald Holmedal, Pål Smith, Vidar Søyseth

Published in: BMC Pulmonary Medicine | Issue 1/2009

Login to get access

Abstract

Background

Cardiac Troponin T (cTnT) elevation during exacerbations of chronic obstructive pulmonary disease (COPD) is associated with increased mortality the first year after hospital discharge. The factors associated with cTnT elevation in COPD are not known.

Methods

From our hospital's database, all patients admitted with COPD exacerbation in 2000–03 were identified. 441 had measurement of cTnT performed. Levels of cTnT ≥ 0.04 μg/l were considered elevated. Clinical and historical data were retrieved from patient records, hospital and laboratory databases. Odds ratios for cTnT elevation were calculated using logistic regression.

Results

120 patients (27%) had elevated cTnT levels. The covariates independently associated with elevated cTnT were increasing neutrophil count, creatinine concentration, heart rate and Cardiac Infarction Injury Score (CIIS), and decreasing hemoglobin concentration. The adjusted odds ratios (95% confidence intervals in parentheses) for cTnT elevation were 1.52 (1.20–1.94) for a 5 × 106/ml increase in neutrophils, 1.21 (1.12–1.32) for a 10 μmol/l increase in creatinine, 0.80 (0.69–0.92) for a 1 mg/dl increase in hemoglobin, 1.24 (1.09–1.42) for a 10 beats/minute increase in heart rate and 1.44 (1.15–1.82) for a 10 point increase in CIIS.

Conclusion

Multiple factors are associated with cTnT elevation, probably reflecting the wide panorama of comorbid conditions typically seen in COPD. The positive association between neutrophils and cTnT elevation is compatible with the concept that an exaggerated inflammatory response in COPD exacerbation may predispose for myocardial injury.
Literature
1.
go back to reference Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997, 349 (9064): 1498-1504.CrossRefPubMed Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997, 349 (9064): 1498-1504.CrossRefPubMed
3.
go back to reference McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007, 62: 411-415.CrossRefPubMedPubMedCentral McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA: Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007, 62: 411-415.CrossRefPubMedPubMedCentral
4.
go back to reference Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: role of comorbidities. Eur Respir J. 2006, 28: 1245-1257.CrossRefPubMed Sin DD, Anthonisen NR, Soriano JB, Agusti AG: Mortality in COPD: role of comorbidities. Eur Respir J. 2006, 28: 1245-1257.CrossRefPubMed
5.
go back to reference Myocardial infarction redefined – A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J. 2000, 21: 1502-1513. Myocardial infarction redefined – A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J. 2000, 21: 1502-1513.
6.
go back to reference Becattini C, Vedovati MC, Agnelli G: Prognostic Value of Troponins in Acute Pulmonary Embolism: A Meta-Analysis. Circulation. 2007, 116: 427-433.CrossRefPubMed Becattini C, Vedovati MC, Agnelli G: Prognostic Value of Troponins in Acute Pulmonary Embolism: A Meta-Analysis. Circulation. 2007, 116: 427-433.CrossRefPubMed
7.
go back to reference Ammann P, Maggiorini M, Bertel O, Haenseler E, Joller-Jemelka HI, Oechslin E, Minder EI, Rickli H, Fehr T: Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003, 41: 2004-2009.CrossRefPubMed Ammann P, Maggiorini M, Bertel O, Haenseler E, Joller-Jemelka HI, Oechslin E, Minder EI, Rickli H, Fehr T: Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003, 41: 2004-2009.CrossRefPubMed
8.
go back to reference Jensen JK, Kristensen SR, Bak S, Atar D, Hoilund-Carlsen PF, Mickley H: Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol. 2007, 99: 108-112.CrossRefPubMed Jensen JK, Kristensen SR, Bak S, Atar D, Hoilund-Carlsen PF, Mickley H: Frequency and significance of troponin T elevation in acute ischemic stroke. Am J Cardiol. 2007, 99: 108-112.CrossRefPubMed
9.
go back to reference Perna ER, Macin SM, Canella JPC, Augier N, Stival JLR, Cialzeta JR, Pitzus AE, Garcia EH, Obregon R, Brizuela M, et al: Ongoing Myocardial Injury in Stable Severe Heart Failure: Value of Cardiac Troponin T Monitoring for High-Risk Patient Identification. Circulation. 2004, 110: 2376-2382.CrossRefPubMed Perna ER, Macin SM, Canella JPC, Augier N, Stival JLR, Cialzeta JR, Pitzus AE, Garcia EH, Obregon R, Brizuela M, et al: Ongoing Myocardial Injury in Stable Severe Heart Failure: Value of Cardiac Troponin T Monitoring for High-Risk Patient Identification. Circulation. 2004, 110: 2376-2382.CrossRefPubMed
10.
go back to reference Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V: Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J. 2008, 31: 563-570.CrossRefPubMed Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V: Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur Respir J. 2008, 31: 563-570.CrossRefPubMed
11.
go back to reference Baillard C, Boussarsar M, Fosse JP, Girou E, Le Toumelin P, Cracco C, Jaber S, Cohen Y, Brochard L: Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med. 2003, 29: 584-589.CrossRefPubMed Baillard C, Boussarsar M, Fosse JP, Girou E, Le Toumelin P, Cracco C, Jaber S, Cohen Y, Brochard L: Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med. 2003, 29: 584-589.CrossRefPubMed
12.
go back to reference Dekker JM, Schouten EG, Kromhout D, Klootwijk P, Pool J: The Cardiac-Infarction Injury Score and Coronary Heart-Disease in Middle-Aged and Elderly Men – the Zutphen Study. J Clin Epidemiol. 1995, 48: 833-840.CrossRefPubMed Dekker JM, Schouten EG, Kromhout D, Klootwijk P, Pool J: The Cardiac-Infarction Injury Score and Coronary Heart-Disease in Middle-Aged and Elderly Men – the Zutphen Study. J Clin Epidemiol. 1995, 48: 833-840.CrossRefPubMed
13.
go back to reference Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung-Volumes and Forced Ventilatory Flows – Report Working Party Standardization of Lung-Function Tests European-Community for Steel and Coal – Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993, 16: 5-40.CrossRefPubMed Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung-Volumes and Forced Ventilatory Flows – Report Working Party Standardization of Lung-Function Tests European-Community for Steel and Coal – Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993, 16: 5-40.CrossRefPubMed
14.
go back to reference Hosmer DW, Lemeshow S: Model-building strategies and methods. Applied logistic regression. 2000, John Wiley & Sons, Inc, 91-142. 2CrossRef Hosmer DW, Lemeshow S: Model-building strategies and methods. Applied logistic regression. 2000, John Wiley & Sons, Inc, 91-142. 2CrossRef
15.
go back to reference Kemp M, Donovan J, Higham H, Hooper J: Biochemical markers of myocardial injury. Br J Anaesth. 2004, 93: 63-73.CrossRefPubMed Kemp M, Donovan J, Higham H, Hooper J: Biochemical markers of myocardial injury. Br J Anaesth. 2004, 93: 63-73.CrossRefPubMed
16.
go back to reference Mair J: Tissue release of cardiac markers: from physiology to clinical applications. Clin Chem Lab Med. 1999, 37: 1077-1084.CrossRefPubMed Mair J: Tissue release of cardiac markers: from physiology to clinical applications. Clin Chem Lab Med. 1999, 37: 1077-1084.CrossRefPubMed
17.
go back to reference Jeremias A, Gibson CM: Narrative Review: Alternative Causes for Elevated Cardiac Troponin Levels when Acute Coronary Syndromes Are Excluded. Ann Intern Med. 2005, 142: 786-791.CrossRefPubMed Jeremias A, Gibson CM: Narrative Review: Alternative Causes for Elevated Cardiac Troponin Levels when Acute Coronary Syndromes Are Excluded. Ann Intern Med. 2005, 142: 786-791.CrossRefPubMed
18.
go back to reference Bakshi TK, Choo MKF, Edwards CC, Scott AG, Hart HH, Armstrong GP: Causes of elevated troponin I with a normal coronary angiogram. Internal Medicine Journal. 2002, 32: 520-525.CrossRefPubMed Bakshi TK, Choo MKF, Edwards CC, Scott AG, Hart HH, Armstrong GP: Causes of elevated troponin I with a normal coronary angiogram. Internal Medicine Journal. 2002, 32: 520-525.CrossRefPubMed
19.
go back to reference Lee PC, Kini AS, Ahsan C, Fisher E, Sharma SK: Anemia Is an Independent Predictor of Mortality After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2004, 44: 541-546.CrossRefPubMed Lee PC, Kini AS, Ahsan C, Fisher E, Sharma SK: Anemia Is an Independent Predictor of Mortality After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2004, 44: 541-546.CrossRefPubMed
20.
go back to reference Alcalai R, Planer D, Culhaoglu A, Osman A, Pollak A, Lotan C: Acute Coronary Syndrome vs Nonspecific Troponin Elevation: Clinical Predictors and Survival Analysis. Arch Intern Med. 2007, 167: 276-281.CrossRefPubMed Alcalai R, Planer D, Culhaoglu A, Osman A, Pollak A, Lotan C: Acute Coronary Syndrome vs Nonspecific Troponin Elevation: Clinical Predictors and Survival Analysis. Arch Intern Med. 2007, 167: 276-281.CrossRefPubMed
21.
go back to reference Freda BJ, Tang WHW, Van Lente F, Peacock WF, Francis GS: Cardiac troponins in renal insufficiency: Review and clinical implications. J Am Coll Cardiol. 2002, 40: 2065-2071.CrossRefPubMed Freda BJ, Tang WHW, Van Lente F, Peacock WF, Francis GS: Cardiac troponins in renal insufficiency: Review and clinical implications. J Am Coll Cardiol. 2002, 40: 2065-2071.CrossRefPubMed
22.
go back to reference Pettersen CA, Adler KB: Airways Inflammation and COPD: Epithelial-Neutrophil Interactions. Chest. 2002, 121: 142S-150.CrossRefPubMed Pettersen CA, Adler KB: Airways Inflammation and COPD: Epithelial-Neutrophil Interactions. Chest. 2002, 121: 142S-150.CrossRefPubMed
23.
go back to reference Wouters EFM: Local and Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc. 2005, 2: 26-33.CrossRefPubMed Wouters EFM: Local and Systemic Inflammation in Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc. 2005, 2: 26-33.CrossRefPubMed
24.
go back to reference Hansson GK: Inflammation, Atherosclerosis, and Coronary Artery Disease. N Engl J Med. 2005, 352: 1685-1695.CrossRefPubMed Hansson GK: Inflammation, Atherosclerosis, and Coronary Artery Disease. N Engl J Med. 2005, 352: 1685-1695.CrossRefPubMed
25.
go back to reference Madjid M, Awan I, Willerson JT, Casscells SW: Leukocyte count and coronary heart disease: Implications for risk assessment. J Am Coll Cardiol. 2004, 44: 1945-1956.CrossRefPubMed Madjid M, Awan I, Willerson JT, Casscells SW: Leukocyte count and coronary heart disease: Implications for risk assessment. J Am Coll Cardiol. 2004, 44: 1945-1956.CrossRefPubMed
26.
go back to reference Huiart L, Ernst P, Ranouil X, Suissa S: Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J. 2005, 25: 634-639.CrossRefPubMed Huiart L, Ernst P, Ranouil X, Suissa S: Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J. 2005, 25: 634-639.CrossRefPubMed
27.
go back to reference Lofdahl CG, Postma DS, Pride NB, Boe J, Thoren A: Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J. 2007, doi:10.1183/09031936.00128806 Lofdahl CG, Postma DS, Pride NB, Boe J, Thoren A: Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J. 2007, doi:10.1183/09031936.00128806
28.
go back to reference Rautaharju PM, Warren JW, Jain U, Wolf HK, Nielsen CL: Cardiac-Infarction Injury Score – An Electrocardiographic Coding Scheme for Ischemic-Heart-Disease. Circulation. 1981, 64: 249-256.CrossRefPubMed Rautaharju PM, Warren JW, Jain U, Wolf HK, Nielsen CL: Cardiac-Infarction Injury Score – An Electrocardiographic Coding Scheme for Ischemic-Heart-Disease. Circulation. 1981, 64: 249-256.CrossRefPubMed
29.
go back to reference Richardson K, Engel G, Yamazaki T, Chun S, Froelicher VF: Electrocardiographic damage scores and cardiovascular mortality. Am Heart J. 2005, 149: 458-463.CrossRefPubMed Richardson K, Engel G, Yamazaki T, Chun S, Froelicher VF: Electrocardiographic damage scores and cardiovascular mortality. Am Heart J. 2005, 149: 458-463.CrossRefPubMed
30.
go back to reference Sin DD, Man SFP: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003, 107: 1514-1519.CrossRefPubMed Sin DD, Man SFP: Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003, 107: 1514-1519.CrossRefPubMed
31.
go back to reference Brekke PH, Omland T, Smith P, Soyseth V: Underdiagnosis of myocardial infarction in COPD – Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med. 2008, 102: 1243-1247.CrossRefPubMed Brekke PH, Omland T, Smith P, Soyseth V: Underdiagnosis of myocardial infarction in COPD – Cardiac Infarction Injury Score (CIIS) in patients hospitalised for COPD exacerbation. Respir Med. 2008, 102: 1243-1247.CrossRefPubMed
32.
go back to reference Harvey MG, Hancox RJ: Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg Med Australas. 2004, 16: 212-215.CrossRefPubMed Harvey MG, Hancox RJ: Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg Med Australas. 2004, 16: 212-215.CrossRefPubMed
33.
go back to reference Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001, 163: 1256-1276.CrossRefPubMed Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001, 163: 1256-1276.CrossRefPubMed
34.
go back to reference Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006, 61: 23-28.CrossRefPubMed Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR: C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006, 61: 23-28.CrossRefPubMed
35.
go back to reference Sin DD, Lacy P, York E, Man SFP: Effects of Fluticasone on Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2004, 170: 760-765.CrossRefPubMed Sin DD, Lacy P, York E, Man SFP: Effects of Fluticasone on Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2004, 170: 760-765.CrossRefPubMed
Metadata
Title
Determinants of cardiac troponin T elevation in COPD exacerbation – a cross-sectional study
Authors
Pål H Brekke
Torbjørn Omland
Stein Harald Holmedal
Pål Smith
Vidar Søyseth
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2009
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-9-35

Other articles of this Issue 1/2009

BMC Pulmonary Medicine 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.